Catherine H Smith

List of Publications by Year
in descending order

238 papers	16,592 citations	13827 67 h-index	18075 120 g-index
248 all docs	248 docs citations	248 times ranked	14461 citing authors

#	Article	IF	Citations
1	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nature Genetics, 2010, 42, 985-990.	9.4	918
2	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 2012, 44, 1341-1348.	9.4	848
3	Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 2011, 303, 1-10.	1.1	690
4	European S3â€Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1-70.	1.3	683
5	Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis. American Journal of Human Genetics, 2011, 89, 432-437.	2.6	468
6	British Association of Dermatologistsâ€™ guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology, 2009, 161, 987-1019.	1.4	412
7	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. British Journal of Dermatology, 2018, 178, 1083-1101.	1.4	380
8	European S3â€Guidelines on the systemic treatment of psoriasis vulgaris â€“ Update 2015 â€“ Short version â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-2294.	1.3	353
9	Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ ILC3 in Psoriasis. Journal of Investigative Dermatology, 2014, 134, 984-991.	0.3	329
10	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015, 135, 2632-2640.	0.3	318
11	Identification of a Novel Proinflammatory Human Skin-Homing Vî³9Vî´2 T Cell Subset with a Potential Role in Psoriasis. Journal of Immunology, 2011, 187, 2783-2793.	0.4	301
12	European consensus statement on phenotypes of pustular psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1792-1799.	1.3	269
13	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology, 2005, 153, 486-497.	1.4	245
14	Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2002, 109, 539-546.	1.5	230
15	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Journal of Dermatology, 2017, 177, 628-636.	1.4	226
16	Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 2013, 133, 2340-2346.	0.3	224
17	U.K. guidelines for the management of Stevensâ€“Johnson syndrome/toxic epidermal necrolysis in adults 2016. British Journal of Dermatology, 2016, 174, 1194-1227.	1.4	199
18	Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology, 2019, 143, 1021-1026.	1.5	165

#	Article	IF	Citations
19	Genome-wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms. American Journal of Human Genetics, 2015, 96, 104-120.	2.6	163
20	Guidelines for the management of tinea capitis. British Journal of Dermatology, 2000, 143, 53-58.	1.4	156
21	Atopic dermatitis: the skin barrier and beyond. British Journal of Dermatology, 2019, 180, 464-474.	1.4	156
22	AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. American Journal of Human Genetics, 2014, 94, 790-797.	2.6	153
23	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€“ Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2461-2498.	1.3	149
24	Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes. Journal of Investigative Dermatology, 2013, 133, 1366-1369.	0.3	140
25	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€”insights from a global registryâ€“based study. Journal of Allergy and Clinical Immunology, 2021, 147, 60-71.	1.5	136
26	The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatology, The, 2021, 3, e627-e637.	2.2	132
27	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. British Journal of Dermatology, 2020, 183, 628-637.	1.4	131
28	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	130
29	AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production. Journal of Investigative Dermatology, 2016, 136, 2251-2259.	0.3	128
30	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 2019, 143, 2120-2130.	1.5	128
31	Mutations in the Î³-Secretase Genes NCSTN , PSENEN , and PSEN1 Underlie Rare Forms of Hidradenitis Suppurativa (Acne Inversa). Journal of Investigative Dermatology, 2012, 132, 2459-2461.	0.3	126
32	Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. British Journal of Dermatology, 2005, 152, 444-450.	1.4	124
33	An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. Science Translational Medicine, 2017, 9, .	5.8	124
34	0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. British Journal of Dermatology, 2004, 150, 554-562.	1.4	122
35	European S3â€Guideline on the systemic treatment of psoriasis vulgaris â€“ Update Apremilast and Secukinumab â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1951-1963.	1.3	116
36	IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. Journal of Allergy and Clinical Immunology, 2015, 135, 1067-1070.e9.	1.5	115

#	Article	IF	Citations
37	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis. JAMA Dermatology, 2020, 156, 131.	2.0	110
38	Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. Journal of Investigative Dermatology, 2008, 128, 1925-1929.	0.3	109
39	The British Association of Dermatologistsâ€™ Biologic Interventions Register (BADBIR): design, methodology and objectives. British Journal of Dermatology, 2012, 166, 545-554.	1.4	108
40	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. Journal of Investigative Dermatology, 2017, 137, 1646-1654.	0.3	108
41	Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis. Journal of Investigative Dermatology, 2013, 133, 1904-1907.	0.3	107
42	Interaction between Genetic Control of Vascular Endothelial Growth Factor Production and Retinoid Responsiveness in Psoriasis. Journal of Investigative Dermatology, 2006, 126, 453-459.	0.3	105
43	Polymorphisms in Folate, Pyrimidine, and Purine Metabolism Are Associated with Efficacy and Toxicity of Methotrexate in Psoriasis. Journal of Investigative Dermatology, 2007, 127, 1860-1867.	0.3	104
44	PSENEN and NCSTN Mutations in Familial Hidradenitis Suppurativa (Acne Inversa). Journal of Investigative Dermatology, 2011, 131, 1568-1570.	0.3	103
45	Psoriasis and its management. BMJ: British Medical Journal, 2006, 333, 380-384.	2.4	100
46	Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury. Clinical Pharmacology and Therapeutics, 2011, 89, 896-901.	2.3	99
47	Excess melanocytic nevi in children with renal allografts. Journal of the American Academy of Dermatology, 1993, 28, 51-55.	0.6	98
48	Risk of cancer in patients with psoriasis on biological therapies: a systematic review. British Journal of Dermatology, 2018, 178, 103-113.	1.4	95
49	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. Journal of Investigative Dermatology, 2015, 135, 2964-2970.	0.3	89
50	A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. British Journal of Dermatology, 2001, 144, 321-327.	1.4	88
51	Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. British Journal of Dermatology, 2017, 176, 1028-1034.	1.4	88
52	Psoriasis treat to target: defining outcomes in psoriasis using data from a realâ€world, populationâ€based cohort study (the British Association of Dermatologists Biologics and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 137 Td	1.4	88
53	Demographics and disease characteristics of patients with psoriasis enrolled in the <scp>B</scp> ritish <scp>A</scp> ssociation of <scp>D</scp> ermatologists <scp>B</scp> iologic <scp>I</scp> nterventions <scp>R</scp> egister. British Journal of Dermatology, 2015, 173, 510-518.	1.4	87
54	British Association of Dermatologistsâ€™ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. British Journal of Dermatology, 2016, 175, 23-44.	1.4	86

#	Article	IF	Citations
55	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	2.8	86
56	Mast cell number and phenotype in chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology, 1995, 96, 360-364.	1.5	85
57	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 2020, 183, 294-302.	1.4	85
58	Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. Journal of Investigative Dermatology, 2011, 131, 1981-1986.	0.3	84
59	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€“ Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 281-317.	1.3	84
60	A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment after First and Repeated Application to Children with Atopic Dermatitis. Journal of Investigative Dermatology, 2005, 124, 695-699.	0.3	82
61	Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02. Nature Communications, 2019, 10, 1150.	5.8	82
62	Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. British Journal of Dermatology, 2013, 168, 954-967.	1.4	81
63	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology, 2013, 52, 1754-1757.	0.9	79
64	Antinuclear antibodies associate with loss of response to antitumour necrosis factor-Î± therapy in psoriasis: a retrospective, observational study. British Journal of Dermatology, 2010, 162, 780-785.	1.4	76
65	Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. Journal of Investigative Dermatology, 2017, 137, 2484-2490.	0.3	75
66	Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. British Journal of Dermatology, 2006, 154, 345-352.	1.4	74
67	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 758-764.	1.3	74
68	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 2018, 154, 581.	2.0	74
69	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 2019, 180, 1069-1076.	1.4	74
70	Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. British Journal of Dermatology, 2014, 171, 17-29.	1.4	72
71	A 4-year follow-up study of atopic dermatitis therapy with 0Â·1% tacrolimus ointment in children and adult patients. British Journal of Dermatology, 2008, 159, 942-951.	1.4	71
72	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 775-784.	0.3	71

#	Article	IF	Citations
73	Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatology, 2017, 56, 2109-2113.	0.9	70
74	Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris. Nature Communications, 2014, 5, 4020.	5.8	68
75	UK guidelines for the management of Stevensâ€“Johnson syndrome/toxic epidermal necrolysis in adults 2016. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2016, 69, e119-e153.	0.5	67
76	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatology, The, 2022, 4, e42-e52.	2.2	66
77	Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. British Journal of Dermatology, 2013, 169, 306-313.	1.4	65
78	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. British Journal of Dermatology, 2009, 160, 438-441.	1.4	64
79	IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. Journal of Investigative Dermatology, 2020, 140, 816-826.e3.	0.3	64
80	Assessment and management of psoriasis: summary of NICE guidance. BMJ, The, 2012, 345, e6712-e6712.	3.0	63
81	A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNFâ€antagonists. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e131-5.	1.3	63
82	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 2016, 136, 1584-1591.	0.3	63
83	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: AÂProspective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 534-541.	0.3	62
84	Long-term Safety and Efficacy of Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Children. Acta Dermato-Venereologica, 2007, 87, 54-61.	0.6	61
85	Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatology, The, 2022, 4, e490-e506.	2.2	61
86	Defining the Therapeutic Range for AdalimumabÂand Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. Journal of Investigative Dermatology, 2019, 139, 115-123.	0.3	60
87	Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. British Journal of Dermatology, 2004, 151, 492-496.	1.4	56
88	Psoriasis and Cardiometabolic Traits: Modest Association but Distinct Genetic Architectures. Journal of Investigative Dermatology, 2015, 135, 1283-1293.	0.3	56
89	Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic. British Journal of Dermatology, 2019, 181, 946-953.	1.4	56
90	Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. Journal of the American Academy of Dermatology, 2012, 66, 317-322.	0.6	55

#	Article	IF	Citations
91	A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. British Journal of Dermatology, 2010, 163, 807-816.	1.4	54
92	Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. British Journal of Dermatology, 2020, 182, 714-720.	1.4	54
93	Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network metaâ€analysis. British Journal of Dermatology, 2020, 183, 638-649.	1.4	54
94	Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. British Journal of Dermatology, 2010, 162, 427-434.	1.4	53
95	Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. British Journal of Dermatology, 2014, 171, 267-273.	1.4	52
96	The IL23R A/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients. Journal of Investigative Dermatology, 2013, 133, 2381-2389.	0.3	51
97	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Annals of the Rheumatic Diseases, 2017, 76, 1774-1779.	0.5	51
98	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 2017, 176, 1297-1307.	1.4	50
99	Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. Annals of the Rheumatic Diseases, 2018, 77, 277-280.	0.5	50
100	Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. British Journal of Dermatology, 2006, 155, 160-169.	1.4	49
101	Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. Nature Communications, 2018, 9, 5075.	5.8	48
102	Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. British Journal of Dermatology, 2019, 181, 1068-1070.	1.4	47
103	Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1440-1448.	1.3	47
104	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. American Journal of Human Genetics, 2020, 107, 539-543.	2.6	44
105	Adhesion Molecules in Allergic Inflammation. The American Review of Respiratory Disease, 1993, 148, S75-S78.	2.9	41
106	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics, 2017, 26, 4301-4313.	1.4	41
107	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Science Translational Medicine, 2019, 11, .	5.8	41
108	Exposure to biological therapies during conception and pregnancy: a systematic review. British Journal of Dermatology, 2018, 178, 95-102.	1.4	40

#	Article	IF	Citations
109	Cutaneous responses to vasoactive intestinal polypeptide in chronic idiopathic urticaria. Lancet, The, 1992, 339, 91-93.	6.3	39
110	Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. British Journal of Dermatology, 2014, 170, 1237-1247.	1.4	39
111	Genetic architecture of acne vulgaris. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1978-1990.	1.3	39
112	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (<scp>BADBIR</scp>). British Journal of Dermatology, 2019, 180, 329-337.	1.4	36
113	Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Clinical and Experimental Allergy, 2006, 36, 1115-1121.	1.4	35
114	A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: â€˜AGREE-ingâ€™ on a common base for European evidence-based psoriasis treatment guidelines. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 782-787.	1.3	34
115	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. British Journal of Dermatology, 2012, 166, 189-195.	1.4	34
116	CYP1A1 Enzymatic Activity Influences Skin Inflammation Via Regulation of the AHR Pathway. Journal of Investigative Dermatology, 2021, 141, 1553-1563.e3.	0.3	34
117	Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. British Journal of Dermatology, 2005, 152, 152-154.	1.4	33
118	On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1458-1467.	1.3	33
119	A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. British Journal of Dermatology, 2011, 164, 26-32.	1.4	32
120	A case of chromoblastomycosis responding to treatment with itraconazole. British Journal of Dermatology, 1993, 128, 436-439.	1.4	30
121	Establishing an Academicâ€“Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. Journal of Investigative Dermatology, 2015, 135, 2903-2907.	0.3	30
122	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. JAMA Dermatology, 2019, 155, 1235.	2.0	30
123	Updated guidance for writing a British Association of Dermatologists clinical guideline: the adoption of the <scp>GRADE</scp> methodology 2016. British Journal of Dermatology, 2017, 176, 44-51.	1.4	29
124	Care of patients with psoriasis: an audit of U.K. services in secondary care. British Journal of Dermatology, 2009, 160, 557-564.	1.4	27
125	Adalimumab for psoriasis patients who are nonâ€responders to etanercept: openâ€label prospective evaluation. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1394-1397.	1.3	27
126	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 769-778.	1.3	27

#	Article	IF	Citations
127	Realâ€world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a singleâ€centre, prospective 1â€year observational cohort study of the first 100 patients treated. British Journal of Dermatology, 2021, 184, 755-757.	1.4	27
128	A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis. Clinical and Experimental Dermatology, 2000, 25, 580-583.	0.6	26
129	Riskâ€mitigating behaviours in people with inflammatory skin and joint disease during the COVIDâ€19 pandemic differ by treatment type: a crossâ€sectional patient survey*. British Journal of Dermatology, 2021, 185, 80-90.	1.4	26
130	Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. Journal of Dermatological Treatment, 2013, 24, 38-49.	1.1	25
131	Loss of IL36RN Function Does Not Confer Susceptibility to Psoriasis Vulgaris. Journal of Investigative Dermatology, 2014, 134, 271-273.	0.3	25
132	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. British Journal of Dermatology, 2017, 177, 1410-1421.	1.4	24
133	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology, 2019, 58, 144-148.	0.9	24
134	Pharmacogenetics in clinical dermatology. British Journal of Dermatology, 2002, 146, 2-6.	1.4	23
135	Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. British Journal of Dermatology, 2013, 168, 1095-1105.	1.4	23
136	Enhanced NF-ÎºB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nature Communications, 2021, 12, 4741.	5.8	23
137	Genome-wide association meta-analysis identifies 29 new acne susceptibility loci. Nature Communications, 2022, 13, 702.	5.8	23
138	Infliximab for the treatment of psoriasis in the U.K.: 9â€ƒyearsâ€™ experience of infusion reactions at a single centre. British Journal of Dermatology, 2012, 167, 411-416.	1.4	22
139	Anakinra for palmoplantar pustulosis: results from a randomized, doubleâ€blind, multicentre, twoâ€staged, adaptive placeboâ€controlled trial (APRICOT)*. British Journal of Dermatology, 2022, 186, 245-256.	1.4	22
140	Biomarkers of disease progression in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 481-493.	1.4	22
141	Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. British Journal of Dermatology, 2010, 163, 889-892.	1.4	21
142	Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. British Journal of Dermatology, 2012, 167, 165-173.	1.4	21
143	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. Arthritis Care and Research, 2014, 66, 1410-1416.	1.5	21
144	The influence of 2020 coronavirus lockdown on presentation of oral and maxillofacial trauma to a central London hospital. British Journal of Oral and Maxillofacial Surgery, 2021, 59, 102-105.	0.4	21

#	Article	IF	Citations
145	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. Journal of Allergy and Clinical Immunology, 2022, 150, 882-893.	1.5	21
146	How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Review of Clinical Immunology, 2010, 6, 957-966.	1.3	20
147	Diffuse plane xanthomatosis and acquired palmoplantar keratoderma in association with myeloma. British Journal of Dermatology, 2006, 132, 286-289.	1.4	19
148	Cell trafficking and role of adhesion molecules in psoriasis. Clinics in Dermatology, 1995, 13, 151-160.	0.8	18
149	Identification of factors that may influence the selection of firstâ€line biological therapy for people with psoriasis: a prospective, multicentre cohort study. British Journal of Dermatology, 2017, 177, 828-836.	1.4	18
150	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. JAMA Dermatology, 2020, 156, 1216.	2.0	18
151	Global reporting of cases of COVIDâ€19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 2020, 183, 404-406.	1.4	18
152	Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity. JAMA Dermatology, 2021, 157, 413.	2.0	18
153	Describing the burden of the COVIDâ€19 pandemic in people with psoriasis: findings from a global crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	1.3	18
154	Prevalence of Advanced Liver Fibrosis in Patients With Severe Psoriasis. JAMA Dermatology, 2019, 155, 1028.	2.0	17
155	Inpatient management of psoriasis: a multicentre service review to establish national admission standards. British Journal of Dermatology, 2007, 158, 266-272.	1.4	15
156	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials, 2018, 19, 465.	0.7	15
157	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and realâ€world populations in psoriasis. British Journal of Dermatology, 2019, 181, 1265-1271.	1.4	15
158	Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab. British Journal of Dermatology, 2019, 181, 385-386.	1.4	15
159	The development of sarcoidosis on antitumour necrosis factor therapy: a paradox. British Journal of Dermatology, 2010, 163, 648-649.	1.4	14
160	Persistence and effectiveness of nonbiologic systemic therapies for moderateâ€toâ€severe psoriasis in adults: a systematic review. British Journal of Dermatology, 2019, 181, 256-264.	1.4	14
161	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis. JAMA Dermatology, 2021, 157, 66.	2.0	14
162	Requirements and expectations of highâ€quality biomarkers for atopic dermatitis and psoriasis in 2021â€"a twoâ€round Delphi survey among international experts. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1467-1476.	1.3	14

#	Article	IF	Citations
163	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 494-506.	1.4	14
164	Systemic treatment of adult atopic dermatitis. Clinical Medicine, 2012, 12, 172-176.	0.8	13
165	Psoriasis biologics: a new era of choice. Lancet, The, 2019, 394, 807-808.	6.3	13
166	T-cell phenotyping uncovers systemic features of atopic dermatitis and psoriasis. Journal of Allergy and Clinical Immunology, 2020, 145, 1021-1025.e15.	1.5	13
167	International collaboration and rapid harmonization across dermatologic COVID-19 registries. Journal of the American Academy of Dermatology, 2020, 83, e261-e266.	0.6	13
168	Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 329-337.	1.3	13
169	Psoriasis: guidance on assessment and referral. Clinical Medicine, 2014, 14, 178-182.	0.8	12
170	Biological Therapies for the Treatment of Severe Psoriasis in Patients with Previous Exposure to Biological Therapy: A Cost-Effectiveness Analysis. Pharmacoeconomics, 2015, 33, 163-177.	1.7	12
171	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 2019, 180, 894-901.	1.4	12
172	Dermatology COVID-19 Registries. Dermatologic Clinics, 2021, 39, 575-585.	1.0	12
173	Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activity. BMJ: British Medical Journal, 2011, 342, d1417-d1417.	2.4	12
174	Hidradenitis suppurativa: haploinsufficiency of gamma-secretase components does not affect gamma-secretase enzyme activityin vitro. British Journal of Dermatology, 2016, 175, 632-635.	1.4	11
175	Differences in Clinical Features and Comorbid Burden between HLA-Câ^—06:02 Carrier Groups in >9,000 People with Psoriasis. Journal of Investigative Dermatology, 2022, 142, 1617-1628.e10.	0.3	11
176	Vaccine hesitancy and access to psoriasis care during the <scp>COVID</scp> â€19 pandemic: findings from a global patientâ€reported crossâ€sectional survey. British Journal of Dermatology, 2022, 187, 254-256.	1.4	11
177	Children with psoriasis and COVIDâ€19: factors associated with an unfavourable COVIDâ€19 course, and the impact of infection on disease progression (Chiâ€PsoCov registry). Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2076-2086.	1.3	11
178	Morphologic Switch From Psoriasiform to Eczematous Dermatitis After Anti-IL-17 Therapy. JAMA Dermatology, 2019, 155, 1082.	2.0	10
179	The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and crossâ€cohort analyses. British Journal of Dermatology, 2021, 185, 1066-1069.	1.4	10
180	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. Scientific Reports, 2021, 11, 23335.	1.6	10

#	Article	IF	Citations
181	Using Realâ€World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokineticâ€Pharmacodynamic Study. Clinical and Translational Science, 2020, 13, 400-409.	1.5	9
182	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clinics in Dermatology, 2021, 39, 467-478.	0.8	9
183	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. British Journal of Dermatology, 2017, 177, 637-644.	1.4	8
184	Biologics for psoriasis: more drugs, new patient categories, but fresh challenges for clinical dermatologists. British Journal of Dermatology, 2017, 177, 7-8.	1.4	8
185	Psychosocial aspects of obesity in adults with psoriasis: A systematic review. Skin Health and Disease, 2021, 1, e33.	0.7	8
186	Eosinophil infiltration into human skin is antigen-dependent in the late-phase reaction. British Journal of Dermatology, 1996, 134, 997-1004.	1.4	8
187	A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report. Wellcome Open Research, 0, 6, 360.	0.9	8
188	Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. Journal of Investigative Dermatology, 2017, 137, 2644-2646.	0.3	7
189	Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal. British Journal of Dermatology, 2018, 179, 50-53.	1.4	7
190	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. Trials, 2020, 21, 158.	0.7	7
191	Cutaneous histamine metabolism in chronic urticaria. Journal of Allergy and Clinical Immunology, 1992, 89, 944-950.	1.5	6
192	Tumour necrosis factor antagonist-induced lupus: a Critically Appraised Topic. British Journal of Dermatology, 2017, 177, 1519-1526.	1.4	6
193	Acne and Telomere Length: A New Spectrum between Senescence and Apoptosis Pathways. Journal of Investigative Dermatology, 2017, 137, 513-515.	0.3	6
194	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Journal of Investigative Dermatology, 2020, 140, 2129-2137.	0.3	6
195	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology, 2022, 61, e255-e266.	0.9	6
196	The value of monitoring ciclosporin concentration 2 hours post-dose (C2) in dermatology: A prospective cohort study. Journal of Dermatological Treatment, 2011, 22, 79-85.	1.1	5
197	Generalized Pustular Eruptions: Time to Adapt the Disease Taxonomy to the Genetic Architecture?. Journal of Investigative Dermatology, 2014, 134, 580-581.	0.3	5
198	Hypercalcaemia-induced kidney injury caused by the vitamin D analogue calcitriol for psoriasis: a note of caution when prescribing topical treatment. Clinical and Experimental Dermatology, 2016, 41, 899-901.	0.6	5

#	Article	IF	Citations
199	Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial. Trials, 2018, 19, 534.	0.7	5
200	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysisâ€"Correction. Journal of Investigative Dermatology, 2021, 141, 177-181.	0.3	5
201	The power and potential of BIOMAP to elucidate hostâ€microbiome interplay in skin inflammatory diseases. Experimental Dermatology, 2021, 30, 1517-1531.	1.4	5
202	Risk factors for mental illness in adults with atopic eczema or psoriasis: protocol for a systematic review. BMJ Open, 2020, 10, e038324.	0.8	5
203	Psoriasis and Cardiovascular Disease: Where Is the Risk?. Journal of Investigative Dermatology, 2013, 133, 2308-2311.	0.3	4
204	The Role of Yeast in Atopic Dermatitis Revisited: a Critical Appraisal. Current Dermatology Reports, 2015, 4, 228-240.	1.1	4
205	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology, 2021, 60, 1588-1592.	0.9	4
206	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e496-e498.	1.3	4
207	Defining trajectories of response in patients with psoriasis treated with biologic therapies. British Journal of Dermatology, 2021, 185, 825-835.	1.4	4
208	Patient preferences for stratified medicine in psoriasis: a discrete choice experiment. British Journal of Dermatology, 2021, 185, 978-987.	1.4	4
209	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. Journal of Investigative Dermatology, 2021, 141, 1872-1878.	0.3	4
210	Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. Dermatology and Therapy, 2022, 12, 195-202.	1.4	4
211	Pitfalls in the determination of diamine oxidase activity. Clinica Chimica Acta, 1991, 201, 89-94.	0.5	3
212	British Guidelines on the Use of Biological Therapies for Psoriasis: A Note of Clarification on the Role of Etanercept. Archives of Dermatology, 2007, 143, 1595-6.	1.7	3
213	Clinical outcomes in patients on secukinumab (Cosentyx^{Â®}) within a specialist psoriasis clinic: a single centre, retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e89-e91.	1.3	3
214	Response to: â€˜Anakinra for palmoplantar pustulosis: results from a randomized, doubleâ€blind, multicentre, twoâ€stage, adaptive placeboâ€controlled trial (APRICOT)â€™: reply from the authors. British Journal of Dermatology, 2022, 186, 909-910.	1.4	3
215	Reply. Journal of Allergy and Clinical Immunology, 2019, 143, 810-811.	1.5	2
216	The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. British Journal of Dermatology, 2020, 183, 981-983.	1.4	2

#	Article	IF	Citations
217	In chronic plaque psoriasis, roflumilast cream safely increased likelihood of clear or almost clear state at 6 weeks. Annals of Internal Medicine, 2020, 173, JC55.	2.0	2
218	Comparison of ALitretinoin with PUVA as the first-line treatment in patients with severe chronic HAnd eczema (ALPHA): study protocol for a randomised controlled trial. BMJ Open, 2022, 12, e060029.	0.8	2
219	The importance of illness severity and multimorbidity in the association between mental health and body weight in psoriasis: Crossâ€sectional and longitudinal analysis. Skin Health and Disease, 0, , .	0.7	2
220	Eosinophil infiltration into human skin is antigen-dependent in the late-phase reaction. British Journal of Dermatology, 1996, 134, 997-1004.	1.4	1
221	The IL23R A/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients. Journal of Investigative Dermatology, 2014, 134, 1779.	0.3	1
222	New blisters in a patient treated for Stevens-Johnson syndrome/toxic epidermal necrolysis. Clinical and Experimental Dermatology, 2014, 39, 63-65.	0.6	1
223	Developing an online patient education resource for topical therapy: a pilot study. British Journal of Dermatology, 2020, 182, 508-509.	1.4	1
224	Characteristics modifying response to biological treatments for psoriasis: considering subgroups in network metaâ€analysis. British Journal of Dermatology, 2021, 184, 358-359.	1.4	1
225	SAT0189â€…Dynamics of circulating tnf during adalimumab treatment of rheumatoid arthritis using a novel drug-tolerant tnf assay. , 2018, , .		1
226	Polyarteritis nodosa presenting as meningoencephalitis. Journal of the Royal Society of Medicine, 1987, 80, 704-5.	1.1	1
227	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. Efficacy and Mechanism Evaluation, 2022, 9, 1-106.	0.9	1
228	Clinicopathological features of Chromoblastomycosisâ€”a case report. British Journal of Dermatology, 1992, 127, 82-83.	1.4	0
229	The International Psoriasis Council Presents Top 10 Psoriasis Research Articles for 2010. Psoriasis Forum, 2010, 16a, 44-51.	0.1	0
230	Systemic antipsoriatic therapy may reverse endothelial dysfunction: reply from authors. British Journal of Dermatology, 2011, 164, 1398-1398.	1.4	0
231	Psoriasis, cardiovascular disease and flowâ€mediated dilatation: reply from authors. British Journal of Dermatology, 2011, 165, 924-925.	1.4	0
232	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. British Journal of Dermatology, 2014, 170, 995-996.	1.4	0
233	THU0004â€…Cross phenotype association mapping of the mhc identifies genetic variants that differentiate psoriatic arthritis from psoriasis. , 2017, , .		0
234	Aldara-induced dermatitis is associated with development of liver fibrosis in mice. British Journal of Dermatology, 2018, 179, 9-10.	1.4	0

#	Article	IF	Citations
235	E099â€ƒAnalysis of referral patterns from a tertiary dermatology service to a tertiary rheumatology service in Guyâ€™s and St Thomasâ€™ hospital. Rheumatology, 2019, 58, .	0.9	0
236	P266â€ƒIL-4/13 inhibitor dupilumab associated with new onset peripheral axial spondyloarthritis in patients with atopic dermatitis. Rheumatology, 2020, 59, .	0.9	0
237	AB0649â€…INFECTION PROFILE OF IMMUNE-MODULATORY DRUGS USED IN AUTOIMMUNE DISEASES: ANALYSIS OF SUMMARY OF PRODUCT CHARACTERISTIC DATA. Annals of the Rheumatic Diseases, 2021, 80, 1357.2-1358.	0.5	0
238	The need for clarity on the use of glucocorticoids for people with psoriatic arthritis: A call for consensus. Rheumatology, 0, , .	0.9	0